Virpax Pharmaceuticals Advances Pain Management Innovations at Industry Conference
- Virpax Pharmaceuticals focuses on non-addictive pain management solutions and central nervous system disorder treatments.
- The company is seeking FDA approval for Probudur™ and Envelta™, innovative pain management drug candidates.
- Virpax is expanding its portfolio with NobrXiol™ for pediatric epilepsy and pursuing partnerships for nonprescription products.
Virpax Pharmaceuticals Showcases Innovations in Pain Management at Key Industry Conference
Virpax Pharmaceuticals, Inc., a company dedicated to developing non-addictive pain management solutions and treatments for central nervous system disorders, highlights its ongoing commitment to advancing healthcare at the upcoming Outsourcing in Clinical Trials (OCT) Conference. Matthew Barnes, the senior director of portfolio management, is set to present at this major event, which attracts over 1,000 industry leaders annually. The conference serves as a crucial platform for sharing insights and strategies aimed at improving clinical trial efficiency while effectively managing costs, a goal that aligns closely with Virpax’s mission to innovate in the pharmaceutical landscape.
The company's focus on developing next-generation pain management products is exemplified by its promising drug candidates currently under development. Notably, Virpax actively seeks FDA approval for Probudur™, a novel single-injection liposomal bupivacaine formulation designed to alleviate post-operative pain. Additionally, Envelta™, an intranasal enkephalin formulation, aims to address both acute and chronic pain, including complications arising from cancer. These innovative treatments reflect Virpax's commitment to creating effective, non-addictive alternatives to traditional pain management therapies, significantly impacting patients' quality of life.
Moreover, Virpax is expanding its portfolio with NobrXiol™, a prescription product targeting pediatric epilepsy, utilizing the company’s proprietary Molecular Envelope Technology. This strategic focus on diverse therapeutic areas not only underscores Virpax's dedication to addressing significant unmet medical needs but also positions the company as a key player in the evolving biopharmaceutical industry. With cooperative research and development agreements already established with the National Institutes of Health and the Department of Defense, Virpax is on a trajectory to enhance its scientific credibility and drive innovation in pain management.
In addition to its pharmaceutical advancements, Virpax Pharmaceuticals also celebrates the recent publication of articles by Dr. Sheila Mathias and Matthew Barnes in the inaugural DIA Global Forum and the 2025 OCT Handbook. These contributions reflect the company’s thought leadership within the industry. Furthermore, Virpax is pursuing partnerships for its nonprescription products, including AnQlar, aimed at inhibiting viral replication from influenza or SARS-CoV-2, and Epoladerm™, a topical diclofenac spray for osteoarthritis pain management. Through these initiatives, Virpax continues to demonstrate its commitment to improving patient care and advancing the field of pain management.